Skip to main content
Caplight Logo









Acrobat Genomics

Acrobat Genomics

Private
San Carlos, CaliforniaHealthcare & Life Scienceshttps://acrobatgenomics.com/

Last Round

Grant

Apr 29, 2026

Total Funding Raised

$228,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Acrobat Genomics is a biotechnology company that develops a drug discovery platform using AI and high-throughput CRISPR gene-editing precision technology to create new therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Defense Tech

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting, Revenue Share

AI Layer

Application

Keywords

AI drug discoverydrug discovery platformgene editingCRISPRbiosecuritytechbioprotein therapeuticsgenerative AIhigh-throughput screeninggenetic diseasesfunctional genomicsbiodefensegene editing inhibitorsmedical countermeasuresdefense tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Acrobat Genomics Comparables

Compare Acrobat Genomics with similar companies based on industry and business-model similarity.

Acrobat Genomics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cassidy Bio
78%
Profluent Bio
71%
Arbor Biotechnologies
71%

Acrobat Genomics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 29, 2026
SeedDec 12, 2022
AcceleratorSep 14, 2022

Key People

Founding team and executive leadership

Nick Hughes

Co-Founder & CEO

Founding Team

Acrobat Genomics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 2, 4x the trailing average.

  • Apr 29, 2026

    Received funding from the Defense Advanced Research Projects Agency.

Acrobat Genomics Filings

Explore SEC and related filing metadata, where available.

Acrobat Genomics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Acrobat Genomics's valuation, stock price, and market status.

Is Acrobat Genomics a public or private company?

Acrobat Genomics is a private company.

What is the current stock price of Acrobat Genomics?

Acrobat Genomics is a private company with no public stock price. No recent secondary market data is available.

How much is Acrobat Genomics worth (valuation)?

Valuation information for Acrobat Genomics is not publicly available.

Can I buy Acrobat Genomics stock?

Acrobat Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Acrobat Genomics's last funding round?

Acrobat Genomics's most recent funding round was Grant on April 29, 2026.

Who are the main investors in Acrobat Genomics?

Key investors in Acrobat Genomics include Illumina Accelerator.

Will Acrobat Genomics IPO soon?

No public IPO plans have been announced for Acrobat Genomics.

How can I track Acrobat Genomics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Acrobat Genomics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Carlos, California
Employee Range5
Year Founded2022
Last FundingApr 29, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?